• Neuroscientific Biopharma to have a pre-IND meeting with US FDA
  • The NSB stock price jumped as high as 30pc this morning
  • Artrya signs first deal in Australia


NSB to have meeting with FDA

NeuroScientific Biopharma (ASX:NSB) jumped as high as 30% this morning after disclosing that it has filed a Pre-Investigation New Drug Application (pre- IND) meeting request with the US FDA.

The filing is for the company’s EmtinB, a drug being developed for the treatment of advanced glaucoma in adults.

NeuroScientific expects the meeting to be held within 60 days.

NeuroScientific chairman, Chris Ntoumenopoulos, said discussing with the FDA the use of EmtinB to treat advanced glaucoma will provide clarity around the company’s planned non-clinical and clinical glaucoma program.

“This will lead us closer to submission of an IND application and our first-in-human studies targeting glaucoma in the US,” said Ntoumenopoulos.

NSB also announced today that following the FDA filing, current non-executive director, Dr Tony Keating, has been appointed as executive director of the company.

Keating will commence initially on a part-time basis, which followed the resignation of Dougal Thring as chief operating officer.

Keating is an experienced entrepreneur and CEO, having co-founded and led ResApp Health from start-up to its ultimate acquisition by Pfizer for $180 million.

“Not only is Dr Keating extremely respected in the industry, but his international network is second to none,” said Ntoumenopoulos.


Artrya nabs first deal in Australia

Meanwhile, Artrya (ASX:AYA) lifted +9% this morning after announcing the first commercial agreement in Australia with The Cardiac Centre NSW.

The 12-month deal is for the use of Artrya’s Salix Coronary Anatomy software for the diagnosis of cardiovascular disease.

Under the terms, Salix will be used across four specialist centres that comprise The Cardiac Centre NSW in Wollongong, Shellharbour, Bowral and Nowra. Collectively, these centres treat more than 25,000 patients per year for heart disease.

Artrya’s AI-driven Salix platform provides full diagnostic and assessment within 10 minutes of first scan, dramatically improving the diagnosis workflow of coronary artery disease, saving unnecessary costs and minimising patient re-admission.

“Artrya delivers what we believe is the most advanced and seamless technology platform on the market for the detection, diagnosis, and care of coronary artery disease, creating a new standard of care for the number one cause of death in the world,” said CEO, Mathew Regan.


Share prices today: